| Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations (NCT05258279) | Juntendo University | 2022-07-01 |
| A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (NCT05338619) | Sung Yong Lee | 2022-06-30 |
| Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC (NCT05394233) | Sichuan Cancer Hospital and Research Institute | 2022-06-01 |
| Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (NCT05245071) | Sanofi | 2022-06-01 |
| Phase 3 Clinical Study of AK112 for NSCLC Patients (NCT05184712) | Akeso | 2022-01-25 |
| Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC (NCT04958811) | Georgetown University | 2021-12-21 |
| A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. (NCT04619433) | Jiangsu HengRui Medicine Co., Ltd. | 2021-02-01 |
| NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial (NCT04698681) | Calithera Biosciences, Inc | 2021-01-19 |
| Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S. (NCT04750824) | Boehringer Ingelheim | 2020-10-15 |
| A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) (NCT04504916) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-10-07 |
| Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. (NCT04453423) | The First Affiliated Hospital with Nanjing Medical University | 2020-07-01 |
| Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 (NCT04396457) | National Hospital Organization Nagoya Medical Center | 2020-05-25 |
| The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer (NCT04206787) | Boehringer Ingelheim | 2020-05-20 |
| A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer (NCT05318443) | Shanghai Institute Of Biological Products | 2020-04-17 |
| Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma (NCT04173338) | Augusta University | 2020-01-23 |
| Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC (NCT04211090) | Sun Yat-sen University | 2020-01-15 |
| The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib (NCT04179890) | Boehringer Ingelheim | 2019-12-17 |
| Study of Crizotinib for ROS1 and MET Activated Lung Cancer (NCT04084717) | University Health Network, Toronto | 2019-12-03 |
| Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC (NCT04063449) | Dong Wang | 2019-08-20 |
| Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure (NCT03802240) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-07-11 |
| Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) (NCT03319316) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-11-01 |
| Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin (NCT03671538) | Lingyu Luo | 2018-10-01 |
| Phase I Study of the Combination of Anlotinib With Gefitinib (NCT03602027) | Second Affiliated Hospital of Nanchang University | 2018-08-01 |
| Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study (NCT03646968) | Yongchang Zhang | 2018-08-01 |
| A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours (NCT03468426) | Boehringer Ingelheim | 2018-07-05 |
| Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel (NCT03566576) | Fujian Cancer Hospital | 2018-07-01 |
| A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer (NCT03329911) | Bio-Thera Solutions | 2017-10-20 |
| A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases (NCT03127319) | Affiliated Hospital of Hebei University | 2017-07-03 |
| Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer (NCT03169335) | Qilu Pharmaceutical Co., Ltd. | 2017-03-28 |
| Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors (NCT02835833) | University of Alabama at Birmingham | 2016-06-09 |
| Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer (NCT02633189) | National Cancer Institute, Naples | 2016-04-01 |
| Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer (NCT01951482) | Sun Yat-sen University | 2016-01-01 |
| Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers (NCT02264990) | AbbVie | 2014-09-30 |
| A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease (NCT01702714) | Hoffmann-La Roche | 2014-07-01 |
| A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (NCT02008227) | Hoffmann-La Roche | 2014-03-11 |
| ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations (NCT01723878) | Hoffmann-La Roche | 2013-12-30 |
| A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer (NCT01995188) | Genentech, Inc. | 2013-12-16 |
| A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation (NCT01887886) | Hoffmann-La Roche | 2013-12-01 |
| An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice (NCT01893268) | Hoffmann-La Roche | 2013-07-25 |
| Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (NCT01829113) | SCRI Development Innovations, LLC | 2013-07-01 |
| A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment (NCT01990261) | Hoffmann-La Roche | 2013-05-01 |
| An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT) (NCT01836133) | Hoffmann-La Roche | 2013-05-01 |
| AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung (NCT01827852) | Hoffmann-La Roche | 2013-03-14 |
| An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC) (NCT01790217) | Hoffmann-La Roche | 2012-07-01 |
| A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations (NCT01609543) | Hoffmann-La Roche | 2012-05-01 |
| A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer (NCT01496742) | Genentech, Inc. | 2012-04-01 |
| A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer (NCT01519804) | Genentech, Inc. | 2012-04-01 |
| A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations (NCT01372384) | Hoffmann-La Roche | 2012-01-01 |
| A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) (NCT01456325) | Genentech, Inc. | 2012-01-01 |
| An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT) (NCT01512420) | Hoffmann-La Roche | 2011-11-01 |
| An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy (NCT01664533) | Hoffmann-La Roche | 2011-09-01 |
| A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) (NCT01351415) | Hoffmann-La Roche | 2011-06-25 |
| Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) (NCT01366131) | Genentech, Inc. | 2011-06-01 |
| A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy (NCT01174563) | Hoffmann-La Roche | 2011-05-23 |
| An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NCT01535729) | Hoffmann-La Roche | 2011-05-01 |
| An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab) (NCT01358942) | Hoffmann-La Roche | 2011-05-01 |
| A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations (NCT01310036) | Hoffmann-La Roche | 2011-04-30 |
| A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER) (NCT01378962) | Hoffmann-La Roche | 2011-03-31 |
| A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations (NCT01260181) | Hoffmann-La Roche | 2011-03-31 |
| A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients. (NCT01250119) | Hoffmann-La Roche | 2011-03-01 |
| Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer (NCT01244191) | Daiichi Sankyo | 2011-01-11 |
| A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer (NCT01185847) | Hoffmann-La Roche | 2010-11-01 |
| A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN) (NCT01204697) | Hoffmann-La Roche | 2010-11-01 |
| An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer (NCT01333007) | Hoffmann-La Roche | 2010-07-01 |
| Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer (NCT01160601) | Peregrine Pharmaceuticals | 2010-06-01 |
| An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NCT01488331) | Hoffmann-La Roche | 2010-06-01 |
| A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer (NCT01077713) | Hoffmann-La Roche | 2010-02-01 |
| Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT01057212) | Providence Health & Services | 2010-02-01 |
| An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer (NCT01070927) | Hoffmann-La Roche | 2010-01-01 |
| A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer (NCT00974584) | Genentech, Inc. | 2009-10-01 |
| Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug (NCT00988936) | Siemens Molecular Imaging | 2009-09-01 |
| Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer (NCT00976456) | PD Dr. med. Wolfgang Schuette | 2009-09-01 |
| AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer (NCT00961415) | Hoffmann-La Roche | 2009-08-01 |
| A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer (NCT00883779) | Hoffmann-La Roche | 2009-04-01 |
| A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NCT01066884) | Hoffmann-La Roche | 2009-04-01 |
| A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. (NCT00776698) | Hoffmann-La Roche | 2009-04-01 |
| A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer. (NCT00773188) | Hoffmann-La Roche | 2008-12-01 |
| A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). (NCT00760929) | Hoffmann-La Roche | 2008-11-10 |
| A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash (NCT00642473) | Hoffmann-La Roche | 2008-02-01 |
| Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants (NCT02596958) | Hoffmann-La Roche | 2007-09-01 |
| A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer. (NCT00518011) | Hoffmann-La Roche | 2007-08-01 |
| A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. (NCT00642824) | Hoffmann-La Roche | 2007-05-01 |
| A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. (NCT00451906) | Hoffmann-La Roche | 2006-08-01 |
| A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer (NCT00152477) | UCB Pharma | 2005-08-15 |
| A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT02774278) | Hoffmann-La Roche | 2005-07-01 |
| A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT00806923) | Hoffmann-La Roche | 2005-02-01 |
| Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (NCT02475382) | Bristol-Myers Squibb | |